No abstract available.
*Angiotensin-Converting Enzyme Inhibitors ; Humans

No abstract available.
Angiotensin-Converting Enzyme Inhibitors* ; Losartan*

Angiotensin converting enzyme inhibitors have a good effects for patients with primary hypertension and in solving some outcomes of the diseases leading to left ventricular insuffiency. The mechanism of the drugs is to bind zinc ion of angiotension converting enzyme. Therefore, the effect of converting angiotensin I into angiotension II was lost. Angiotension II has effect of the smooth muscle stimulation, aldosterone excretion, hemodynamic change, catecholomine release and glucocorticoid exeretion.
Angiotensin-Converting Enzyme Inhibitors ; Pharmaceutical Preparations

No Abstract available.
Angiotensin-Converting Enzyme Inhibitors* ; Angiotensins* ; Peptidyl-Dipeptidase A*

INTRODUCTION: The pandemic caused by coronavirus disease 2019 (COVID-19) posed a serious challenge to all health care systems in the world. It has been found to be harmful in people with underlying cardiovascular diseases, particularly in patients with systemic hypertension, which may be due to upregulation of angiotensin-converting enzyme 2 (ACE2) expression, which may lead to increased severe acute respiratory syndrome coronavirus 2 virulence. Renin-angiotensin system inhibitor (RASI) acts by blocking the angiotensin-converting enzyme and angiotensin II type 1 receptors, which in turn affects the production of the ACE2 protein. Hence, there have been arguments on whether to continue or discontinue this medication. Given the widespread use of RASIs globally and the fact that they are generally cardioprotective, research into the safety of continuing these maintenance medications in patients hospitalized with mild to moderate COVID-19 is immensely needed. METHODS: This meta-analysis involved review of observational studies among hypertensive patients on maintenance ACE inhibitor or angiotensin-receptor blocker with confirmed mild to moderate COVID-19 infection. Analyses were performed to determine the adjusted hazard ratio of each event using the raw data obtained from each study. Random-effects model and Cochran-Mantel-Haenszel method were utilized at 95% confidence interval. To check for heterogeneity, χ2 test and I2 statistic were calculated. Cochrane ReviewManager (RevMan version 5.3) was used for data analysis, and forest plots were generated. RESULTS: At 95% confidence interval, the adjusted hazard ratios for all-cause mortality and intensive care unit (ICU) admission at 95% confidence interval were 1.64 (1.22, 2.21) and 1.93 (1.34, 2.79), respectively. The tests of overall estimate effect for both outcomes were P < 0.0001 for all-cause mortality and P = 0.0003 for ICU admission. CONCLUSION Discontinuation of maintenance RASI during hospitalization is associated with increased all-cause mortality and ICU admission among hypertensive patients with mild to moderate COVID-19 infection.
Angiotensin-Converting Enzyme Inhibitors ; Coronavirus:COVID-19

To evaluate the efficacy and safety of Songling Xuemaikang Capsules combined with conventional Western medicine in the treatment of essential hypertension. PubMed, VIP, CNKI, Wanfang and other databases were retrieved from the establishment of the database to February 2020 for clinical randomized controlled trial(RCT) about Songling Xuemaikang Capsules combined with conventional Western medicine in the treatment of essential hypertension. The literatures were screened out according to the inclusion criteria, and RevMan 5.3 software was used for Meta-analysis. A total of 3 100 patients in 27 RCTs were enrolled. According to Meta-analysis, Songling Xuemaikang Capsules combined with conventional Western medicine could effectively reduce systolic blood pressure(MD=-7.88,95%CI[-9.68,-6.08],P<0.000 01) and diastolic blood pressure(MD=-7.85, 95%CI[-9.07,-6.62], P<0.000 01), triglyceride(MD=-0.46, 95%CI[-0.66,-0.26], P<0.000 01) and total cholesterol(MD=-0.92, 95%CI[-1.49,-0.35], P=0.001), but increase HDL cholesterol(MD=0.51, 95%CI[0.28, 0.73], P<0.000 01), with a better effect than the Western medicine group alone. The results of LDL-C analysis showed that there was no significant difference between the two groups(MD=-0.91, 95%CI[-1.82, 0.01], P=0.05). The subgroup analysis suggested that reduced systolic blood pressure may be related to the use of ARB. There was a close correlation between CCB drugs and the decrease of diastolic blood pressure. In addition, there was no significant difference in the compliance and the incidence of adverse reactions. Clinical application of Songling Xuemaikang Capsules combined with Western medicine in the treatment of patients with essential hypertension has clear efficacy and certain safety. More clinical randomized controlled trials are needed for verification in the future.
Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Capsules ; Drugs, Chinese Herbal ; Essential Hypertension/drug therapy* ; Humans

BACKGROUND: Activation of renin-angiotensin system (RAS) has been an important mechanism of microvascular and macrovascular complications in diabetic patients. It has been reported that RAS blockades reduce the development and progression of diabetic nephropathy. The aim of this study was to evaluate whether valsartan, an angiotensin II receptor blocker (ARB), reduced blood pressure and urinary albumin excretion rate (UAER) in hypertensive type 2 diabetic patients. METHOD: Three hundred forty-seven hypertensive type 2 diabetic patients who had not taken angiotensin converting enzyme inhibitors or ARB for 6 months prior to this study were enrolled. We measured blood pressure and UAER before and after 24 weeks of valsartan treatment. RESULT: Baseline mean systolic and diastolic blood pressure was 143 +/- 15 and 87 +/- 11 mmHg, respectively and the median albumin excretion rate was 27 ug/mg. Reduction in systolic and diastolic blood pressure was 16 mmHg/10 mmHg and the median UAER was 19.3 ug/mg after 24 weeks (P < 0.01, respectively). When we divided the subjects into three groups according to the UAER (normoalbuminuria, microalbuminuria and macroalbuminuria), significant changes were reported in the microalbuminuria and the macroalbuminuria groups. Thirty-eight (42%) patients with microalbuminuria improved to normoalbuminuria and twelve (41%) patients with macroalbuminuria improved to microalbuminuria. We found an association between the improvement of blood pressure and UAER (R = 0.165, P = 0.015). CONCLUSION: We concluded that valsartan reduces urinary albumin excretion and blood pressure in hypertensive type 2 diabetic patients.
Angiotensin-Converting Enzyme Inhibitors ; Angiotensins ; Blood Pressure ; Diabetes Mellitus ; Diabetic Nephropathies ; Humans ; Receptors, Angiotensin ; Renin-Angiotensin System ; Tetrazoles ; Valine ; Valsartan

BACKGROUND AND OBJECTIVES: Angiotensin-converting enzyme inhibitors have the effect of regression of left ventricular hypertrophy which has been known as the adverse prognostic factor in the cardiovascular diseases. There are some reports that patients having low ACE activity are prone to have the ACE inhibitorinduced cough. In this study we evaluate the difference of the regression of left ventricular mass according to ACE inhibitor induced cough. MATERIALS AND METHOD: Newly detected hypertensive patients (N=08) from Jan. 1994 to Dec.1997 without cough and other contraindications to ACEI were prospectively prescribed ACEI and followed up for two years whether they have experienced ACE inhibitor induced cough. Cough and non-cough group are analyzed the amount of regression of left ventricular mass by ECG. RESULTS: Left ventricular mass index decreases significantly from 128 38 to 11936 g/m2(deltaLVMI=9+/-22g/m2, p< 0.05), after ACE inhibitors had been used for two years. There is no difference between cough and non-cough group. When subgroup analysis has been done according to sex and the presence of the baseline left ventricular hypertrophy, LVH(+ group and female have the tendency of the larger amount of decreasing of LVMI than LVH(-) group and male respectively [LVH(+:LVH(-)=15+/-26:-3+/-15, M:F=12+/-24:-7+/-19]. After the adjusting of the influence of baseline LVM and sex, the amount of degree of LVMI regresssion in case of the men without baseline LVH is significantly different in cough and non-cough group. LVMI decreases significantly in non-cough group, but not in cough group. CONCLUSION: ACE inhibitors have the effect of the regression of LVMI by ECG. The amount of change of LVMI is greater in female and the patients with baseline LVH. In case of men without LVH, non-cough group has larger amount of decreasing of LVMI than cough group.
Angiotensin-Converting Enzyme Inhibitors ; Cardiovascular Diseases ; Cough* ; Electrocardiography ; Female ; Humans ; Hypertrophy, Left Ventricular ; Male ; Prospective Studies

BACKGROUND: The efficacy of oral angiotensin converting enzyme(ACE) inhibitors in the treatment of hypertension has been well documented. Fosinopril is a member of a new class of phosphorous containing ACE inhibitors and is a cleared almost equally by both renal and hepatic routes. METHODS: To evaluate the effects of fosinopril, a new angiotensin converting enzyme inhibitors, in patients with mild to moderate essential hypertension, we administered fosinopril 10~40mg/day once daily to 32 patients(14 males, 18 females; range of age, 40~71 years old) with dose titration every 2 weeks. RESULTS: The baseline blood pressure after 4 weeks wash-out period was 156.3+/-22.3/104.8+/-5.93mmHg. After fosinopril therapy, the blood pressure declined to 150.0+/-27.8/96.4+/-12.2mmHg with 10mmg/day and 144.4+/-20.0/95.21+/-9.95mmHg with 20mg/day, 139.6+/-18.3/85.1+/-9.71mmHg with 30mg/day.During the period of maintenance after dose titration of fosinopril every 2 weeks for 8 weeks, the blood pressure were declined statistically significant (p<0.05). But the heart rate was not changed throughout the period of treatment. The efficacy of fosinopril therapy disclosed 26 patients(81.3%) with normalized diastolic blood pressure and 4 patients(11.8%) with more than 10mmHg decline of diastolic blood pressure. Therefore, the efficacy of fosinopril in these particular patients was 93.1% and two patients(6.9%) showed a failure of fosinopril therapy. The adverse reaction due to fosinopril were reported in 3 patients(9.4%) with dry cough, 1 patients(3.1%) with palpitation and 1 patients(3.1%) with dizziness, but there were patients who discontinued fosinopril due to adverse reaction. CONCLUSION: These results suggested that antihypertensive therapy with fosinopril was effective and well tolerated in patients with mild to moderate essential hypertension.
Angiotensin-Converting Enzyme Inhibitors ; Angiotensins ; Blood Pressure ; Cough ; Dizziness ; Female ; Fosinopril* ; Heart Rate ; Humans ; Hypertension* ; Male

OBJECTIVE: Angiotensin-converting enzyme inhibitors have been shown to improve survival in patients with congestive heart failure. To evaluate the efficacy of enalapril in patients with dilated cardiomyopathy during concurrent treatment with digoxin and diuretics, the peak rates of left ventricular movement were assessed after 6 months of follow-up by digitized echocardiography. METHODS: Using a high quality digitizer, continuous measurement of left ventricular dimension and its rate of change (dD/dt) were obtained throughout the cardiac cycle. Normalized rates of wall movement (dD/dt/D) were used for comparison. RESULTS: 1) Compared with control subjects, patients with dilated cardiomyopathy showed much lower Peak(-) dD/dt and Peak(-) dD/dt/D. 2) Peak(+) dD/dt and Peak(+) dD/dt/D were also depressed in patients. 3) Peak dD/dt improved significantly (p<0.05) in the enalapril group (n=16), but did not change in the conventional treatment group (n=20) after 6 months. Peak dD/dt/D improved approximately (p<0.005) in the enalapril group. 5) There were no deaths in 2 treatment groups during initial 6 months, but 3 patients in the conventional treatment group died suddenly during 1 year of follow-up. CONCLUSION: The present study has shown that left ventrieular Peak dD/dt and Peak dD/dt/D are significantly depressed in patients with dilated cardiomyopathy. Enalapril appears to provide well-tolerated and effective long-term therapy by improving peak rates of left ventricular movement in patients with dilated cardiomyopathy.
Angiotensin-Converting Enzyme Inhibitors ; Cardiomyopathy, Dilated* ; Digoxin ; Diuretics ; Echocardiography ; Enalapril* ; Follow-Up Studies ; Heart Failure ; Humans